Introduction {#s1}
============

Cells have evolved mechanisms to regulate fuel utilization in response to changes in substrate availability. Glucose oxidation leads to inhibition of β-oxidation through the production of malonyl-CoA, a potent inhibitor of carnitine palmitoyl transferase-1 (CPT-1) ([@B1]), a gateway into mitochondrial β-oxidation. Conversely, acetyl-CoA, a product of β-oxidation, inhibits pyruvate dehydrogenase ([@B1]), a critical enzyme in the glycolytic pathway. Fatty acids potentiate glucose-stimulated insulin secretion (IS) ([@B2]), and insulin suppresses adipose tissue triglyceride hydrolysis. The inhibitory effect of insulin on adipose tissue lipolysis leads to a decrease in circulating fatty acids and thus comprises a negative feedback loop ([@B3]).

The mechanism by which fatty acids regulate IS is not fully elucidated. Acute exposure to fatty acids stimulates IS, whereas chronic exposure to fatty acids suppresses IS ([@B2]). Chronic fatty acid treatment of β-cells in the presence of high glucose leads to a decrease in the expression of Pdx1, a transcription factor ([@B4]). Pdx1 is required for pancreatic development ([@B4]). Palmitate is incorporated into ceramide, an inhibitor of phosphatidylinositol-3-kinase and Akt, both of which are involved in insulin signaling ([@B5]). Loss of activity of these kinases leads to blunted insulin signaling ([@B1],[@B6]), which has been hypothesized to decrease Pdx1 translocation into the nucleus.

Multiple pathways have been proposed to explain the acute stimulatory effects of fatty acids on IS. Several conventional protein kinase C (PKC) isozymes are activated by fatty acids, which in turn leads to increased IS ([@B7]). Conversely, fatty acids suppress several novel PKC isozymes that inhibit IS, leading to enhanced IS ([@B8]). Fatty acids acutely regulate cellular Ca^2+^ levels through activation of GPR40, leading to enhanced IS ([@B9]).

We previously showed that genetically imposed obesity (*Lep^ob/ob^*) induces the expression of micro-RNAs (miRNAs) 132 and 212 in pancreatic islets ([@B10]). In diabetes-resistant C57BL/6J (B6) mice, the induction was ∼13-fold, whereas in diabetes-susceptible BTBR T (+) tf/J (BTBR) mice, the induction was reduced to approximately threefold. In this study we show that overexpression of these miRNAs enhances IS in response to a variety of secretagogues, suggesting that the strain difference in their regulation may contribute to diabetes susceptibility. We identify the mitochondrial carnitine acyl-carnitine translocase (CACT; *Slc25a20*) as a direct target of the miRNAs that mediates their effect on IS. The downregulation of CACT causes an accumulation of cellular acyl-carnitine molecules and enhances their effect on IS.

Research Design and Methods {#s2}
===========================

Reagents {#s3}
--------

Insulin from INS-1 cells and mouse islets was measured with an in-house ELISA using an anti-insulin antibody from Fitzgerald Industries (Acton, MA). RPMI growth media, Hanks' balanced salt solution, and Lipofectamine 2000 were bought from Life Technologies. Palmitic acid (PA), BSA, palmitoyl-L-carnitine (PC), collagenase type XI, diazoxide (DZX), 8-Br-cAMP, L-arginine, and small interfering RNAs (siRNAs) against CACT (custom siRNA-duplex 5′-CAAAGAAGCUGUAUCAGGA\[dT\]\[dT\] 5′-UCCUGAUACAGCUUCUUUG\[dT\]\[dT\])--negative control scrambled siRNAs (cat. no. SIC001) all were obtained from Sigma-Aldrich (St. Louis, MO). Chemically modified PremiR miRNA precursors and negative control \#1 were purchased from Ambion (Foster City, CA). RNA and miRNA isolation kits were purchased from QIAGEN (Valencia, CA). Antibody against CACT was obtained from Abcam (Cambridge, MA), and antibody against Vdac was a generous gift from Dave Pagliarini, University of Wisconsin-Madison. Goat antirabbit secondary antibodies were purchased from Cell Signaling Technology (Boston, MA). The ^14^C-PA, ^14^C-PC, and ^14^C-U-glucose all were purchased from Perkin Elmer, Inc. POC-16 (palmitoyl carnitine ether), an analog of PC in which the ester linkage between the fatty acid and carnitine is replaced by an ether linkage with C~16~, was a generous gift from the Bronfman laboratory, Pontificia Universidad Católica de Chile. The pmirGLO dual luciferase construct was a generous gift from the Sugden laboratory at University of Wisconsin-Madison.

Cell Lines and Mouse Islet Treatments {#s4}
-------------------------------------

INS-1--derived rat insulinoma cell lines, 832/3 and 832/13, were used in this study. The cells were cultured in RPMI 1640 with 10% FBS and 11 mmol/L glucose, as described by Bhatnagar et al. ([@B11]). Pancreatic islets of Langerhans were isolated from C57BL/6J mice by collagenase digestion and a Ficoll gradient separation as previously described ([@B11]).

Taqman Quantitative PCR Analysis of Selective miRNAs {#s5}
----------------------------------------------------

Fluorogenic Taqman probes for miRNAs 132, 212, and 375 were purchased from Applied Biosystems. Relative expression levels of miRNAs of interest were determined by real-time quantitative PCR using the ABI PRISM 7900 Sequence Detection System from Applied Biosystems. The mRNA level of the *INS-1* gene (the predominant isoform in INS-1 cells) was detected by Taqman quantitative PCR using a specific probe from Applied Biosystems and normalized to β-actin mRNA levels.

Transfection of INS-1 Cells with siRNA/miRNA Oligonucleotides {#s6}
-------------------------------------------------------------

siCACT and negative control oligonucleotides were transfected into INS-1 832/13 or 832/3 cells (∼80 nmol oligonucleotides/500,000 cells) using Lipofectamine 2000, as described previously ([@B11]). Experiments illustrated in [Fig. 2](#F2){ref-type="fig"} and [Supplementary Figs. 1, 2, and 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1677/-/DC1) were performed using the INS-1 832/3 subclone, whereas the remaining experiments used the 832/13 subclone. In our experience, 832/13 cells are generally more adherent and, therefore, more amenable to our studies. The effect of PC or the miRNAs on IS was observed equally in both subclones of the INS-1 cells (data not shown).

Generation of Adenovirus Overexpressing miRNA Oligonucleotides {#s7}
--------------------------------------------------------------

Adenoviruses (Ads) overexpressing miRNAs 132, 212, and 375 were generated in the Duke University core Ad laboratory, as described in [Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1677/-/DC1). The forward and reverse oligonucleotides then were cloned into a Gateway entry plasmid (pENTR1A; Invitrogen), driven by the human ^1^H promoter, and a green fluorescent protein (GFP) expression cassette driven by a cytomegalovirus promoter.

Infection of INS-1 Cells With Ad Overexpressing miRNA Oligonucleotides {#s8}
----------------------------------------------------------------------

After seeding (24 h), cells were treated with the Ads at an multiplicity of infection (MOI) of 10 in OPTIMEM transfection media for 2 h; 48 h later, cells were used for the IS and luciferase reporter studies or harvested for Western blot analysis.

IS Assay {#s9}
--------

The IS assay in INS-1 cells and mouse islets was performed as previously described ([@B11]). The mouse islet IS experiment evoked by PC-BSA included a digitonin pretreatment (20 µg/mL, 20 min at 37°C) to achieve improved penetration of PC, as described previously ([@B12]).

Microarray Expression Profiling {#s10}
-------------------------------

miRNAs 132 and 212 were overexpressed using oligonucleotides in INS-1 832/3 cells. Cells were harvested at both 10 and 24 h. RNA was extracted from the lysate using the QIAGEN (RNeasy) kit. RNA array hybridizations were performed at Rosetta Inpharmatics (Seattle, WA). Profiling was performed as previously described ([@B13]). mRNAs were considered to be differentially expressed (DE) if they were in the top 5% of genes altered by miRNA upregulation.

CACT Protein Quantification {#s11}
---------------------------

Cells were harvested by a Western lysis buffer (20 mmol/L Tris-HCl \[pH 7.5\], 150 mmol/L sodium chloride, 1 mmol/L Na~2~EDTA, 1 mmol/L EGTA, 1% Triton, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L β-glycerophosphate, 1 mmol/L sodium orthovanadate, 1 µg/mL leupeptin, 0.5 mM sodium fluoride, phenylmethylsulfonyl fluoride, and 1 protease inhibitor cocktail tablet) 48 h after infection/transfection. The cell lysates were sonicated and centrifuged at 13,000 × *g* for 10 min. The supernatant was discarded and the pellet was resuspended and sonicated in the same Western lysis buffer with an additional 1% SDS. CACT protein was detected using a rabbit anti-Slc25a20 polyclonal antibody (Abcam) at a dilution of 1:1,000. The CACT protein intensity was normalized to Vdac, an abundant mitochondrial protein, which was detected using a rabbit anti-Vdac polyclonal antibody at a dilution of 1:2,000. Secondary goat antirabbit antibody was used at 1:5,000 dilution. Immunoblotting was performed using a standard protocol ([@B11]).

Luciferase Assay {#s12}
----------------

The 3′ untranslated region (UTR) of the rat CACT gene was fused behind the firefly gene in the pmirGLO expression construct (Promega). This construct also contained a Renilla luciferase gene, which was used to normalize for transfection efficiency, according to the manufacturer's directions. INS-1 832/3 cells were transfected with pmirGLO with or without cotransfection of either Ad-GFP, Ad-miR-132, or Ad-miR-375 (MOI 10) 24 h after seeding. We measured luminescence in INS-1 cells 48 h later using a Tecan M1000 microplate reader.

PA and PC Conjugation to BSA {#s13}
----------------------------

PA was conjugated to BSA by mixing 67 µL of 25 mg/mL palmitate solution (heated to 70°C) with 933 µL of 70 mg/mL BSA solution at 70°C to yield a final concentration of 6 mmol/L palmitate. PC (and POC-16) was conjugated to BSA using the protocol described by Brockenbrough and Korc ([@B14]). Briefly, PC (100 mmol/L) was added to a 3.3% BSA-containing Krebs-Ringers solution and heated to 45°C for 5 min to obtain a 1 mmol/L stock solution of PC-BSA.

β-Oxidation Assay {#s14}
-----------------

After transfection/infection (48 h), the cells were maintained in 1.5 mmol/L glucose for 2 h, followed by a 2-h treatment with PA (300 μmol/L with 0.5 μCi/ml ^14^C-PA), PC (50 μmol/L with 0.1 μCi/ml ^14^C-PC), 1.5 mmol/L glucose, and 1 mmol/L L-carnitine. Following the 2-h incubation period, cellular media were transferred into sealed scintillation vials with a small Eppendorf tube containing 0.3 mL of 1 N sodium hydroxide. To liberate gaseous ^14^CO~2~ from the media, 0.1 mL of 70% perchloric acid was added; the vials were resealed and maintained at room temperature overnight, resulting in carbon dioxide (CO~2~) accumulating in the base. The amount of ^14^CO~2~ produced was determined by liquid scintillation counting of 0.3 mL of the base, and the amounts of acid soluble metabolites ([@B15]) were determined by measuring the amount of ^14^C-labeled metabolite remaining in the media after perchloric acid precipitation.

Glucose Oxidation Assay {#s15}
-----------------------

Glucose oxidation was measured using the same protocol described above for β-oxidation. Cells were treated with 15 mmol/L glucose containing 0.5 μCi/mL ^14^C-glucose for CO~2~ production.

Acyl-Carnitine Profiling in INS-1 Cells {#s16}
---------------------------------------

After transfection, cells were cultured for 48 h in RPMI media supplemented with 1 mmol/L L-carnitine. Following this, cells were maintained in 1.5 mmol/L glucose for 2 h, followed by a 2-h treatment with or without 50 μmol/L ([@B16]) in Krebs-Ringer buffer ([@B11]) containing 1.5 mmol/L glucose. Cells then were harvested and acyl-carnitine esters were determined by MS/MS spectrometry, as previously described ([@B17]).

GPR40 Assay {#s17}
-----------

The GPR40 assay was performed as described by Tan et al. ([@B18]).

Expression of Data and Statistical Analysis {#s18}
-------------------------------------------

Data are expressed as mean ± SEM. Statistical significance was determined using a Student *t* test, which compared the two conditions. A two-way ANOVA was used in cases where more than two conditions were compared. A *P* value \<0.05 was considered statistically significant.

Results {#s19}
=======

miRNAs 132 and 212 Enhance IS from Pancreatic β-Cells {#s20}
-----------------------------------------------------

To evaluate the effects of miRNA 132 on β-cell function, we used an Ad to overexpress the miRNA in INS-1 832/13 cells while monitoring IS. Under these conditions, IS was significantly augmented in response to multiple secretagogues; glucose, potassium chloride (KCl), DZX with high glucose, cAMP, and L-arginine ([Fig. 1](#F1){ref-type="fig"}). In contrast, miRNA-132 did not stimulate IS at basal glucose (1.5 mmol/L). miRNA-212 overexpression also stimulated IS in the presence of glucose and KCl ([Supplementary Fig. 1*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1677/-/DC1)). miRNAs 132 and 212 did not alter insulin mRNA or protein expression ([Supplementary Fig. 1*B* and *C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1677/-/DC1)), indicating that the miRNAs stimulate IS by modulating the insulin secretory pathway. The effects of miRNA-132 on IS are consistent with those described in a recent report ([@B20]). Our positive control, miRNA-375, suppressed IS ([Supplementary Fig. 1*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1677/-/DC1)) without altering insulin mRNA or protein ([Supplementary Fig. 1*B* and *C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1677/-/DC1)), as previously reported ([@B21]). Our negative control, Ad-GFP, did not affect IS compared with nontreated cells ([Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1677/-/DC1)).

![miRNA-132 enhances IS from pancreatic β-cells. The rat-derived β-cell line, INS-1 832/13, was infected with Ad overexpressing Ad-miRNA-132 or Ad-GFP (negative control). IS in response to increasing glucose concentrations or various combinations of glucose and KCl (40 mmol/L), DZX (250 μmol/L), cAMP (3 mmol/L), or L-arginine (15 mmol/L), was measured 48 h after infection. IS is normalized to total cellular protein and expressed as IS (nanograms) normalized for total protein ([@B19]). Each condition was performed six times. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.](3805fig1){#F1}

Mitochondrial CACT Is a Direct Target of miRNAs 132 and 212 {#s21}
-----------------------------------------------------------

While we and another group ([@B20]) showed that miRNAs 132 and 212 stimulate IS, the molecular targets of the miRNAs are unknown. To identify putative targets that mediate the effects of miRNAs 132 and 212 on IS, we overexpressed the miRNAs in INS-1 832/3 cells, followed by whole-genome microarray profiling at 10 h ([Supplementary Fig. 3*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1677/-/DC1)) and 24 h ([Fig. 2*A*](#F2){ref-type="fig"}). Approximately 3,000 genes were DE in response to the miRNAs at both time points ([Supplementary Data 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1677/-/DC1)). Of these two sets of DE genes (assessed at 10 and 24 h), ∼60% were common. Interestingly, only ∼14% of the DE genes contained a seed region for the miRNAs, suggesting that the majority of the DE genes may be indirect targets of the miRNAs. At 10 and 24 h, the mitochondrial CACT was the most downregulated gene (reduced by ∼80%) in response to the overexpression of miRNA 132 or 212. In addition, miRNA-132 caused a ∼60% decrease in the abundance of the CACT protein ([Fig. 2*B*](#F2){ref-type="fig"}).

![miRNA-132 directly targets CACT for downregulation. *A*: Gene expression profiling in INS-1 832/3 cells following miRNA overexpression. Differential expression (DE) resulting from miRNA-132 is plotted against DE for miRNA-212 24 h after overexpression of the miRNAs using oligonucleotides (*P* \< 0.05). Larger circles indicate greater statistical significance of DE. Axes show the log~10~ of the fold-change (miRNA over negative control). Negative values indicate downregulation of expression. *CACT* is highlighted as the most downregulated gene in response to both miRNAs. *B*: miRNA-132 decreases CACT protein level. Western blot analysis was used to evaluate the effect of miRNA-132 on CACT protein levels in INS-1 832/3 cells. Ads were used to overexpress either miRNA-132 or GFP. Cells were harvested 48 h after infection, and 25 µg of protein was loaded in each lane; Vdac protein was used to normalize loading. Blot is representative of three independent experiments. *C*: CACT is the direct target of miRNA-132. INS-1 832/3 β-cells were transfected with a dual luciferase reporter construct that contained the 3′-UTR for the rat *CACT* gene, and one of three viruses (MOI 10): Ad-GFP, Ad-miR-375, or Ad-miR-132 (*n* = 3 experiments for each condition). After 48 h, luminescence in the cells was measured. \**P* \< 0.05; \*\**P* \< 0.01.](3805fig2){#F2}

To demonstrate that CACT mRNA is a direct target of miRNA-132, we cloned the 3′ UTR of CACT into a vector encoding firefly luciferase and Renilla. The overexpression of miRNA-132 resulted in a significant loss (∼40%; *P* \< 0.001) of luciferase activity, whereas miRNA-375 had no effect ([Fig. 2*C*](#F2){ref-type="fig"}). Taken together, these data provide strong evidence that miRNA-132 directly targets CACT expression, leading to a reduction in CACT protein.

Downregulation of CACT Enhances IS from Pancreatic β-Cells {#s22}
----------------------------------------------------------

The mRNA targets of siRNA oligonucleotides are more specific than those of miRNAs. To determine whether CACT is a target gene responsible for the effect of miRNAs 132 and 212 on IS, we asked whether siRNAs that were designed to selectively suppress CACT mimic the effect of the miRNAs on IS. siRNA-mediated suppression of CACT (∼60% mRNA and ∼40% protein; [Supplementary Fig. 4*A* and *B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1677/-/DC1)) resulted in an increase in IS in response to basal glucose ([Fig. 3*A*](#F3){ref-type="fig"}), and, in addition, to all the secretagogues shown to be affected by miRNA 132 ([Fig. 1](#F1){ref-type="fig"}).

![Long-chain carnitine esters are potent insulin secretagogues. *A*: CACT knockdown enhances IS. IS from INS-1 832/13 β-cells was measured in response to siRNA-mediated knockdown of CACT. Cells were transfected with siRNA against CACT or a scrambled oligonucleotide while plating cells (reverse transfection) and incubated for 48 h before measuring IS. IS in response to increasing glucose concentrations (1.5, 7, and 15 mmol/L); elevated KCl (40 mmol/L) at 15 mmol/L glucose; a combination of elevated KCl, 15 mmol/L glucose, and 250 μmol/L DZX; or 3 mmol/L cAMP or 15 mmol/L L-arginine at 7 mmol/L glucose was measured. IS is normalized to total cellular protein and expressed as IS (nanograms) normalized for total protein ([@B19]). Each condition was performed five or more times. \**P* \< 0.05; \*\**P* \< 0.01. *B*: PC mimics the stimulatory effect of CACT knockdown on IS. IS in INS-1 832/13 cells in response to exogenous PC-BSA (15, 30, and 50 μmol/L), alone or in combination with CACT suppression by siRNA oligonucleotides, was measured. Cells were transfected with siRNAs CACT or negative control oligonucleotides (Scr-siRNA). After 48 h, IS was stimulated with 1.5 mmol/L glucose alone or in the presence of PC-BSA. IS is normalized to total cellular protein. Experiments were done a total three times. ANOVA calculation showed that *P* \< 0.01 (\#) for dose-dependent effect of PC-BSA compared with no addition of PC on either scrambled or siCACT transfected cells. \*\*\**P* \< 0.001 for effect of CACT knockdown. *C*: PC potentiates IS from primary mouse islets. Islets were isolated from B6 mice and used for ex vivo IS assays. After purification, islets were maintained in Krebs-Ringer buffer media at 1.7 mmol/L glucose for 20 min in the presence of digitonin (20 µg/mL) and then for 45 min without digitonin (preincubation), followed by a 45-min incubation with 1.7 mmol/L glucose in the presence of 10, 25, and 50 μmol/L PC to stimulate IS. IS was quantified using an insulin ELISA and normalized to total insulin content in islets. All experiments were performed three times (except the effect at 10 μmol/L PC-BSA, which was observed twice). \**P* \< 0.05.](3805fig3){#F3}

CACT is located in the inner mitochondrial membrane and mediates the influx of fatty acyl-carnitine esters into the mitochondria in preparation for β-oxidation ([@B22]). We hypothesized that the miRNA-dependent downregulation of CACT leads to reduced β-oxidation and elevates cellular levels of acyl-carnitine molecules, which in turn promote IS.

To test this hypothesis, we first asked whether a long-chain fatty acyl-carnitine stimulates IS when directly added to pancreatic β-cells. At 15--50 μmol/L, PC ([@B16]) resulted in a dose-dependent increase in IS in the presence of 1.5 mmol/L glucose ([Fig. 3*B*](#F3){ref-type="fig"}). Knockdown of CACT by siRNAs further increased the effect of PC on IS. In addition to INS-1 832/13 cells, PC promoted a dose-dependent increase in IS from cultured mouse islets ([Fig. 3*C*](#F3){ref-type="fig"}).

In addition to PC, 50 μmol/L stearoyl-carnitine also promoted IS from INS-1 832/3 β-cells ([Supplementary Fig. 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1677/-/DC1)). Finally, 600 μmol/L nonesterified palmitate augmented IS when acutely added to INS-1 832/3 cells ([Supplementary Fig. 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1677/-/DC1)), as has been previously reported ([@B2]).

CACT Knockdown Reduces β-Oxidation {#s23}
----------------------------------

A reduction in CACT protein may lead to reduced β-oxidation because of diminished mitochondrial import of acyl-carnitine molecules. By decreasing the production of acetyl-CoA, glucose oxidation may increase because of the derepression of pyruvate dehydrogenase, as predicted by the Randle hypothesis ([@B1]). To discriminate between reduced β-oxidation and enhanced glycolysis in response to knockdown of CACT, we measured rates of palmitate, PC, and glucose oxidation in INS-1 832/13 cells. Palmitate and PC oxidation were significantly reduced by siRNA against CACT and by miRNA 132 ([Fig. 4*A* and *B*](#F4){ref-type="fig"}). Glucose oxidation was significantly suppressed by siRNA against CACT, whereas miRNA 132 caused a small increase in glucose oxidation ([Fig. 4*C*](#F4){ref-type="fig"}).

![CACT knockdown reduces β-oxidation and leads to acyl-carnitine accumulation. *A--C*: siCACT and miRNA 132 both blunt β-oxidation. INS-1 832/13 cells were transfected with CACT siRNAs or scrambled (Scr) oligonucleotides as negative control or were infected with Ad-GFP or Ad-miRNA-132. Palmitate oxidation (^14^CO~2~ released and ASM) (*A*), palmitoyl-carnitine oxidation (^14^CO~2~ released and ASM) (*B*), and glucose oxidation (*C*) were measured 48 h after transfection/infection, as described in [Research Design and Methods]{.smallcaps}. Units for all the graphs are nanomoles ^14^C per milligram protein per hour. *D, E*: Metabolic profile demonstrates an accumulation of acyl-carnitines in response to CACT downregulation. INS-1 832/13 cells were transfected with CACT siRNAs or control oligonucleotides (Scr-siRNA) and maintained for 48 h in RPMI supplemented with 1 mmol/L L-carnitine. The culture medium was refreshed without (*D*) or with (*E*) PC (50 μmol/L) and 1.5 mmol/L glucose 2 h before harvesting the cells for metabolic profiling. All metabolite measurements in response to CACT siRNA are normalized to control measurements. All bars represent statistically significant upregulation in metabolites. All experiments were performed three times.\**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.](3805fig4){#F4}

CACT Knockdown Increases Cellular Acyl-Carnitine Concentrations {#s24}
---------------------------------------------------------------

We used mass spectrometry--based metabolic profiling to survey the pool of acyl-carnitines in INS-1 832/13 cells in the presence and absence of exogenous acyl-carnitine (50 μmol/L PC). In response to siRNA-mediated knockdown of CACT, we found that long-chain acyl-carnitine esters, ranging from C-14 to C-20, were significantly increased (1.5- to 2-fold; *P* \< 0.05) ([Fig. 4*D*](#F4){ref-type="fig"}). PC resulted in a significant elevation in carnitine esters with short- and long-chain lengths in response to CACT knockdown ([Fig. 4*E*](#F4){ref-type="fig"}). This experiment was performed while maintaining a chronic exogenous level of L-carnitine (1 mmol/L for 48 h) to ensure that free carnitine concentrations were not limiting for CPT-1 activity. These studies were repeated in the absence of exogenous L-carnitine ([Supplementary Fig. 6*A* and *B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1677/-/DC1)), revealing that under these conditions CACT knockdown led to an increase in fewer long-chain acyl-carnitines. Absolute concentrations for all acyl-carnitine molecules profiled in both studies are provided in [Supplementary Data 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1677/-/DC1).

A Nonhydrolyzable Palmitoyl-Carnitine Analog (POC-16) Enhances IS {#s25}
-----------------------------------------------------------------

To determine whether long-chain carnitine esters are direct insulin segretagogues, we asked whether a nonhydrolyzable analog of PC promotes IS. In contrast to PC, the POC-16 analog lacks the C1 carbonyl group and contains an alcohol attached to C2, yielding an ether linkage between the fatty acyl group and carnitine ([Fig. 5*A*](#F5){ref-type="fig"}). This ether linkage renders POC-16 nonhydrolyzable ([@B23]). We hypothesized that if PC is a direct signaling molecule that affects IS, then POC-16 should mimic the effect of PC. POC-16 was as effective as PC in promoting IS ([Figs. 3*B*](#F3){ref-type="fig"} and [5*B*](#F5){ref-type="fig"}). POC-16 enhanced IS at basal glucose by ∼90%, and the effect was augmented ∼2.5-fold when coupled with knockdown of CACT. This supports our hypothesis that cytosolic PC acts directly to promote IS.

![A nonhydrolyzable analog of PC enhances glucose-stimulated IS. *A*: Molecular structure of PC and POC-16, an analog of PC in which the ester linkage between the fatty acid and carnitine is replaced by an ether linkage with C~16~. *B*: POC-16 stimulates IS from INS-1 832/13 cells. IS was monitored 48 h after cells were treated with either CACT siRNAs or negative control siRNAs (Scr) in the presence or absence of POC-16 (10 μmol/L, conjugated to BSA) and 1.5 mmol/L glucose. Insulin secreted was normalized to total cellular protein. The experiment was performed four times. \*\**P* \< 0.01; \*\*\**P* \< 0.001.](3805fig5){#F5}

Discussion {#s26}
==========

In this study we show that fatty acyl-carnitines are potent stimulators of IS. Upregulation of miRNAs 132 and 212 in pancreatic β-cells results in CACT suppression. CACT inhibition leads to inhibition of β-oxidation and accumulation of cellular long-chain fatty acyl-carnitine esters. In addition to carnitine esters, we also show that POC-16, a nonhydrolyzable analog of PC ([@B23]), is capable of enhancing IS ([Fig. 5*B*](#F5){ref-type="fig"}), suggesting that the bond between the hydrocarbon and carnitine does not need to be hydrolyzed to stimulate IS.

The role of fatty acids in IS has been extensively studied. Herrero et al. ([@B24]) showed that overexpression of a mutant form of CPT-1 that is insensitive to malonyl-CoA leads to enhanced β-oxidation and impaired IS. Furthermore, islets from mice deficient in peroxisome proliferator--activated receptor-α decreased β-oxidation and increased IS ([@B25],[@B26]). However, Mulder et al. ([@B27]) and Boucher et al. ([@B28]) showed that overexpression of malonyl-CoA decarboxylase leads to increased β-oxidation without affecting IS. However, these studies did not measure acyl-carnitines during manipulations of β-oxidation. Our data support an inverse relationship between β-oxidation and IS: reduced oxidation leads to increased secretion in parallel with increases in long-chain acyl-carnitines. In a recent review, Prentki et al. ([@B2]) also suggest that CPT-1 is a negative modulator of IS, which, when highly active, channels free fatty acids for β-oxidation, decreasing the production of lipid amplification signals of IS. A recent study by Klett et al. ([@B29]) also showed the importance of both acyl-CoAs and acyl-CoA synthetase for IS. These studies collectively demonstrate the importance of fatty acids and their analogs in IS.

miRNAs 132 and 212 are located within ∼200 base pairs of each other in the rat, mouse, and human genomes, suggesting that they are likely generated from a common primary miRNA precursor molecule ([@B30]). These miRNAs have a ∼75% sequence similarity and a ∼97% similar list of putative target genes ([@B31]). A genome-wide screen identified miRNAs 132 and 212 as targets of the transcription factor cAMP-response element binding protein ([@B30]). Accordingly, expression of these miRNAs is increased in response to an elevation in cellular cAMP, a signaling molecule that is critical for IS and β-cell survival ([@B32],[@B33]). Recent publications also showed that, along with obesity and diabetes, high-fat feeding leads to an increase in the levels of miRNA 132 ([@B20]). In our mouse models, miRNAs 132 and 212 both were upregulated in islets in response to obesity, but this occurred to a lesser extent in diabetic mice. Moreover, our data show that CACT, a direct target of the miRNAs, is highly upregulated in diabetic obese mice compared with nondiabetic obese mice ([@B34]). These results suggest that the miRNA-dependent downregulation of CACT may be a mechanism to enhance the insulin secretory response.

In humans, CACT deficiency is a rare autosomal recessive disease and is characterized by a diminished capacity for β-oxidation, which can lead to a variety of severe metabolic disorders, including hypoketotic hypoglycemia, hyperammonemia, cardiac and hepatic dysfunction, skeletal muscle weakness, and encephalopathy ([@B22],[@B35]). These phenotypes primarily reflect defects in muscle and hepatic β-oxidation. An early diagnostic criterion for CACT deficiency in humans is accumulation of plasma long-chain acyl-carnitines ([@B22]). Deletion of steroid receptor coactivator-3 in mice, which regulates CACT, leads to metabolic consequences similar to those that occur in CACT deficiency ([@B36]). Our results demonstrate that these same lipid classes significantly increase in β-cells in response to CACT knockdown ([Fig. 4*D* and *E*](#F4){ref-type="fig"}). Long-chain fatty acyl-carnitines showed a stronger correlation with IS ([Fig. 3*B*](#F3){ref-type="fig"}) than did short-chain fatty acyl-carnitines, with the exception of C5 ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1677/-/DC1)). This agrees with previous findings indicating that long-chain fatty acids are more potent insulin secretagogues ([@B7]). C5 carnitine inhibits β-oxidation by antagonizing butyryl-CoA and octanoyl-CoA dehydrogenase ([@B37]). However, others have argued that acyl-carnitines are not associated with the regulation of IS. Glasgow et al. ([@B38]) measured steady-state insulin in response to chronically elevated long-chain acyl-carnitines, whereas we focused our studies on acute regulation of IS. Pepin et al. ([@B39]) showed that acute exposure to L-3-hydroxybutyrate or L-3-hydroxyglutarate did not change IS. However, our studies used long-chain fatty acyl-carnitines.

Surprisingly, we observed a slight decrease in glucose oxidation in response to CACT knockdown in addition to reduced β-oxidation. Because CACT is responsible for a bidirectional flux of acyl-carnitines, it is possible that CACT knockdown leads to an accumulation of acetyl-CoA in the mitochondrial matrix, leading to inhibition of glycolysis.

Our results demonstrate that long-chain acyl-carnitine esters are insulin secretagogues. The role of fatty acyl-CoA molecules in promoting IS has been widely studied ([@B40]); however, the mechanism is not well understood. Palmitoyl-CoA accumulation is known to increase protein acylation, which also leads to increased IS ([@B41]). Studies involving a neuroblastoma cell line show that, in addition to palmitoyl-CoA, PC could also be involved in protein palmitoylation ([@B42]). However, POC-16 is not a substrate for protein palmitoylation, suggesting that PC is unlikely to regulate IS through palmitoylation. Fatty acids also have been shown to regulate cellular Ca^2+^ levels through activation of GPR40 ([@B41]), leading to enhanced IS. However, we did not observe an effect of PC on GPR40 activation ([Supplementary Fig. 7](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1677/-/DC1)).

PC negatively regulates conventional and atypical PKCs ([@B43],[@B44]). In addition, POC-16 suppresses conventional PKCs ([@B17]). Phosphatidylserine (PS) rescues the inhibitory effect of POC-16 on conventional PKC activity, suggesting that POC-16 may bind to the PS-binding domain on PKCs ([@B43]). PS binds to both the C~1~ and C~2~ domains of PKCs ([@B45]), indicating that PC could act as a ligand for either or both of these domains. PKCs have been shown to be both positive ([@B23],[@B43]) and negative regulators of IS ([@B45]), indicating that PC could act as a ligand for either or both of these domains. PKCs have been shown to be positive ([@B46],[@B47]) as well as negative regulators of IS ([@B48],[@B49]).

siCACT enhanced IS at low glucose, suggesting that acyl-carnitines do not require glucose metabolism to influence IS. Several key components of the insulin secretory machinery, for example, synaptotagmins and Munc13 homologs, contain C~1~ and/or C~2~ domains ([@B50]), raising the possibility that fatty acyl-carnitines may directly interact with these proteins to regulate their function. Cytosolic accumulation of fatty acyl-CoA caused by reduced β-oxidation can lead to increased synthesis of diacylglycerol, monoacylglycerol, and phospholipids ([@B2],[@B7]). A recent study by Zhao et al. ([@B51]) suggests that monoacylglycerols can bind the C~1~ domain of Munc13-1, a critical protein involved in vesicle exocytosis, and thus mediate enhanced insulin exocytosis.

In addition to stimulating secretion by binding exocytosis-mediating proteins, PC and other acyl-carnitines activate voltage-dependent calcium channels ([@B52]). PC can suppress or activate L-type calcium channels ([@B53],[@B54]), depending on experimental conditions. PC activates the ryanodine receptor responsible for intracellular calcium--induced calcium response ([@B55]). PC also has been shown to inhibit K-ATP channels in ventricular myocytes ([@B56]), suggesting a mechanism by which PC could promote Ca^2+^ influx, leading to enhanced IS.

Acyl-carnitines have recently become a biomarker in metabolic syndrome ([@B57],[@B58]). Our studies show that fatty acyl-carnitines are potent insulin secretagogues. These molecules are elevated in the sera of patients with insulin resistance ([@B57]). Elevated acyl-carnitine molecules, as observed with CACT suppression or in humans with CACT mutations ([@B22]), could be associated with increased IS that occurs in subjects with metabolic syndromes. The resulting hyperinsulinemia could lead to insulin resistance.
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======================

###### Supplementary Data

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1677/-/DC1>.
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